TY  - JOUR
AU  - Peg, Vicente
AU  - López-García, María Ángeles
AU  - Comerma, Laura
AU  - Peiró, Gloria
AU  - García-Caballero, Tomás
AU  - López, Ángel Concha
AU  - Suárez-Gauthier, Ana
AU  - Ruiz, Irune
AU  - Rojo, Federico
PY  - 2020
DO  - 10.2217/fon-2020-1100
UR  - http://hdl.handle.net/10668/16754
T2  - Future oncology (London, England)
AB  - Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of...
LA  - en
KW  - PD-L1
KW  - antibody
KW  - breast cancer
KW  - diagnosis
KW  - immunohistochemistry
KW  - immunotherapy
KW  - Antibodies, Monoclonal
KW  - B7-H1 Antigen
KW  - Biomarkers, Tumor
KW  - Clinical Decision-Making
KW  - Disease Management
KW  - Female
KW  - Humans
KW  - Immunohistochemistry
KW  - Molecular Targeted Therapy
KW  - Neoplasm Metastasis
KW  - Neoplasm Staging
KW  - Triple Negative Breast Neoplasms
TI  - PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion.
TY  - research article
VL  - 17
ER  -